FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Antiviral Res / A treatment for and vaccine against the deadly Hendra and Ni...
Antiviral research2013; 100(1); 8-13; doi: 10.1016/j.antiviral.2013.06.012

A treatment for and vaccine against the deadly Hendra and Nipah viruses.

Abstract: Hendra virus and Nipah virus are bat-borne paramyxoviruses that are the prototypic members of the genus Henipavirus. The henipaviruses emerged in the 1990s, spilling over from their natural bat hosts and causing serious disease outbreaks in humans and livestock. Hendra virus emerged in Australia and since 1994 there have been 7 human infections with 4 case fatalities. Nipah virus first appeared in Malaysia and subsequent outbreaks have occurred in Bangladesh and India. In total, there have been an estimated 582 human cases of Nipah virus and of these, 54% were fatal. Their broad species tropism and ability to cause fatal respiratory and/or neurologic disease in humans and animals make them important transboundary biological threats. Recent experimental findings in animals have demonstrated that a human monoclonal antibody targeting the viral G glycoprotein is an effective post-exposure treatment against Hendra and Nipah virus infection. In addition, a subunit vaccine based on the G glycoprotein of Hendra virus affords protection against Hendra and Nipah virus challenge. The vaccine has been developed for use in horses in Australia and is the first vaccine against a Biosafety Level-4 (BSL-4) agent to be licensed and commercially deployed. Together, these advances offer viable approaches to address Hendra and Nipah virus infection of livestock and people.
Published by Elsevier B.V.
Get Full Text
Publication Date: 2013-07-06 PubMed ID: 23838047PubMed Central: PMC4418552DOI: 10.1016/j.antiviral.2013.06.012Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • N.I.H.
  • Intramural
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article pertains to the development of an effective post-exposure treatment and a vaccine against the deadly Hendra and Nipah viruses, both of which originate from bat hosts. The treatment involves a monoclonal antibody targeting the viruses’ G glycoprotein, while the vaccine is created from the G glycoprotein of the Hendra virus.

Background of Hendra and Nipah Viruses

  • The Hendra and Nipah viruses are bat-borne paramyxoviruses, and they are the first known members of the Henipavirus genus.
  • These viruses emerged in the 1990s and have since caused significant disease outbreaks in both humans and livestock.
  • The Hendra virus first appeared in Australia, where it has led to seven human infections and four fatalities since 1994.
  • The Nipah virus initially surfaced in Malaysia, with successive outbreaks happening in Bangladesh and India. So far, there have been an estimated 582 human cases of Nipah virus infection, with a fatality rate of 54%.

Significance of the Viruses

  • The extensive species tropism and the viruses’ ability to induce lethal respiratory and/or neurological illness make the Hendra and Nipah viruses significant transboundary biological threats.

Development of Treatment and Vaccine

  • Recent experimental discoveries in animals have shown that a human monoclonal antibody targeting the viral G glycoprotein is a successful post-exposure treatment for Hendra and Nipah virus infections.
  • Apart from the treatment, a subunit vaccine based on the G glycoprotein of the Hendra virus has been developed. This vaccine successfully offers protection against the Hendra and Nipah viruses.

Vaccine Deployment

  • The vaccine has been developed for use in horses in Australia, and it is the first vaccine against a Biosafety Level-4 (BSL-4) agent to be licensed and commercially available.
  • This vaccine and post-exposure treatment represent significant advances in dealing with Hendra and Nipah virus infections in both livestock and humans, offering viable strategies to manage these viral infections.

Cite This Article

APA
Broder CC, Xu K, Nikolov DB, Zhu Z, Dimitrov DS, Middleton D, Pallister J, Geisbert TW, Bossart KN, Wang LF. (2013). A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Res, 100(1), 8-13. https://doi.org/10.1016/j.antiviral.2013.06.012

Publication

Antiviral research
ISSN: 1872-9096
NlmUniqueID: 8109699
Country: Netherlands
Language: English
Volume: 100
Issue: 1
Pages: 8-13

Researcher Affiliations

Broder, Christopher C
  • Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, United States. Electronic address: christopher.broder@usuhs.edu.
Xu, Kai
    Nikolov, Dimitar B
      Zhu, Zhongyu
        Dimitrov, Dimiter S
          Middleton, Deborah
            Pallister, Jackie
              Geisbert, Thomas W
                Bossart, Katharine N
                  Wang, Lin-Fa

                    MeSH Terms

                    • Animals
                    • Antibodies, Monoclonal / therapeutic use
                    • Cattle
                    • Cattle Diseases / drug therapy
                    • Cattle Diseases / immunology
                    • Cattle Diseases / prevention & control
                    • Hendra Virus / drug effects
                    • Hendra Virus / genetics
                    • Hendra Virus / immunology
                    • Henipavirus Infections / drug therapy
                    • Henipavirus Infections / immunology
                    • Henipavirus Infections / prevention & control
                    • Henipavirus Infections / veterinary
                    • Humans
                    • Nipah Virus / drug effects
                    • Nipah Virus / genetics
                    • Nipah Virus / immunology
                    • Viral Vaccines / administration & dosage
                    • Viral Vaccines / genetics
                    • Viral Vaccines / immunology

                    Grant Funding

                    • R01 AI054715 / NIAID NIH HHS
                    • U01 AI077995 / NIAID NIH HHS
                    • Intramural NIH HHS

                    Conflict of Interest Statement

                    Conflict of interest. CCB, ZZ and DSD are United States federal employees. CCB, DSD and ZZ are coinventors on patents pertaining to human monoclonal antibodies against Hendra and Nipah viruses, and CCB and KNB are coinventors on patents pertaining to soluble forms of Hendra and Nipah G glycoproteins; assignees are The United States of America as represented by the Department of Health and Human Services (Washington, DC), Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (Bethesda, MD). All other authors declare no competing interests.

                    References

                    This article includes 61 references
                    1. Abdullah S, Chang LY, Rahmat K, Goh KT, Tan CT. Late-onset Nipah virus encephalitis 11 years after the initial outbreak: A case report.. Neurology Asia 2012;17:71–74.
                    2. Aguilar HC, Iorio RM. Henipavirus membrane fusion and viral entry.. Curr Top Microbiol Immunol 2012;359:79–94.
                      pubmed: 22427111
                    3. Aljofan M, Saubern S, Meyer AG, Marsh G, Meers J, Mungall BA. Characteristics of Nipah virus and Hendra virus replication in different cell lines and their suitability for antiviral screening.. Virus Res 2009;142:92–99.
                      pmc: PMC2744099pubmed: 19428741
                    4. . Hendra virus, human, equine - Australia (02): Queensland, Pro-med. International Society for Infectious Diseases; 2009a. Aug 21, archive no. 20090826.2998. Available at www.promedmail.org.
                    5. . Hendra virus, human, equine - Australia (04): Queensland, fatal, Pro-med. International Society for Infectious Diseases; 2009b. Sep 3, p. archive no. 20090903.3098. Available at www.promedmail.org.
                    6. . International Society for Infectious Diseases; 2009c. Sep 10, Hendra virus, human, equine - Australia (05): Queensland, Pro-med; p. archive no. 20090910.3189. Available at www.promedmail.org.
                    7. . Hendra virus, equine - Australia (05): Queensland: human exposure. Pro-MED. International Society for Infectious Diseases; 2010. May 27, p. archive no. 20100527.1761. Available at www.promedmail.org.
                    8. . Hendra virus, equine - Australia (08) Queensland: possible human case. Pro-med. International Society for Infectious Diseases; 2012a. Jul 19, p. archive no. 20120720.1208397. Available at www.promedmail.org.
                    9. . Hendra virus, equine - Australia (12): Queensland: vaccine. Pro-med. International Society for Infectious Diseases; 2012b. Nov 3, p. archive no. 20121104.1390394. Available at www.promedmail.org.
                    10. . Hendra virus. The State of Queensland, Department of Agriculture, Fisheries and Forestry, Queensland Government; 2013a. Available at www.daff.qld.gov.au/4790_20801.htm.
                    11. . Hendra virus, equine - Australia: (02) Queensland. Pro-med. International Society for Infectious Diseases; 2013b. Feb 22, p. archive no. 20130224.1557005. Available at www.promedmail.org.
                    12. . Nipah encephalitis, human - Bangladesh (03), Pro-med. International Society for Infectious Diseases; 2013c. Feb 5, p. archive no. 20130205.1530748. Available at www.promedmail.org.
                    13. Balzer M. Hendra vaccine success announced.. Aust Vet J 2011;89:N2–3.
                      pubmed: 21834199
                    14. Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR, Choudhary A, Wang LF, Eaton BT, Broder CC. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble g glycoprotein of hendra virus.. J Virol 2005;79:6690–6702.
                      pmc: PMC1112112pubmed: 15890907
                    15. Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, Yan L, Feng YR, Brining D, Scott D, Wang Y, Dimitrov AS, Callison J, Chan YP, Hickey AC, Dimitrov DS, Broder CC, Rockx B. A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge.. Sci Transl Med 2011;3:105ra103.
                      pmc: PMC3313625pubmed: 22013123
                    16. Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, Lacasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC, Broder CC, Feldmann H, Geisbert TW. A hendra virus g glycoprotein subunit vaccine protects african green monkeys from nipah virus challenge.. Sci Transl Med 2012;4:146ra107.
                      pmc: PMC3516289pubmed: 22875827
                    17. Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern JA, Green D, Hancock TJ, Chan YP, Hickey AC, Dimitrov DS, Wang LF, Broder CC. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection.. PLoS Pathog 2009;5:e1000642.
                      pmc: PMC2765826pubmed: 19888339
                    18. Broder CC. Therapeutics and Vaccines against Hendra and Nipah Viruses.. In: Levine MM, Dougan G, Good MF, Liu MA, Nabel GJ, Nataro JP, Rappuoli R, editors. New Generation Vaccines. 4. Informa Healthcare; USA, New York: 2010. pp. 885–894.
                    19. Broder CC. Henipavirus outbreaks to antivirals: the current status of potential therapeutics.. Curr Opin Virol 2012;2:176–187.
                      pmc: PMC4347837pubmed: 22482714
                    20. Broder CC, Geisbert TW, Xu K, Nikolov DB, Wang LF, Middleton D, Pallister J, Bossart KN. Immunization Strategies Against Henipaviruses.. Curr Top Microbiol Immunol 2012;359:197–223.
                      pmc: PMC4465348pubmed: 22481140
                    21. Chong HT, Kamarulzaman A, Tan CT, Goh KJ, Thayaparan T, Kunjapan SR, Chew NK, Chua KB, Lam SK. Treatment of acute Nipah encephalitis with ribavirin.. Ann Neurol 2001;49:810–813.
                      pubmed: 11409437
                    22. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, Ksiazek TG, Rollin PE, Zaki SR, Shieh W, Goldsmith CS, Gubler DJ, Roehrig JT, Eaton B, Gould AR, Olson J, Field H, Daniels P, Ling AE, Peters CJ, Anderson LJ, Mahy BW. Nipah virus: a recently emergent deadly paramyxovirus.. Science 2000;288:1432–1435.
                      pubmed: 10827955
                    23. Colgrave ML, Snelling HJ, Shiell BJ, Feng YR, Chan YP, Bossart KN, Xu K, Nikolov DB, Broder CC, Michalski WP. Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus.. Glycobiology 2011;22:572–584.
                      pmc: PMC3287018pubmed: 22171062
                    24. Dolgin E. Animal rule for drug approval creates a jungle of confusion.. Nat Med 2013;19:118–119.
                      pubmed: 23389593
                    25. Freiberg AN, Worthy MN, Lee B, Holbrook MR. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection.. J Gen Virol 2010;91:765–772.
                      pmc: PMC2888097pubmed: 19889926
                    26. Geisbert TW, Feldmann H, Broder CC. Animal Challenge Models of Henipavirus Infection and Pathogenesis.. Curr Top Microbiol Immunol 2012;359:153–177.
                      pmc: PMC7120132pubmed: 22476556
                    27. Georges-Courbot MC, Contamin H, Faure C, Loth P, Baize S, Leyssen P, Neyts J, Deubel V. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection.. Antimicrob Agents Chemother 2006;50:1768–1772.
                      pmc: PMC1472238pubmed: 16641448
                    28. Guest A. The World Today.. ABC News (Australian Broadcasting Corporation) 2012. Experimental therapy for Hendra virus patient.
                    29. Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, Chua KB, Lam SK, Buckland R, Deubel V, Wild TF. Nipah virus: vaccination and passive protection studies in a hamster model.. J Virol 2004;78:834–840.
                      pmc: PMC368848pubmed: 14694115
                    30. Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, Deubel V, Buckland R, Wild TF. Antibody Prophylaxis and Therapy against Nipah Virus Infection in Hamsters.. J Virol 2006;80:1972–1978.
                      pmc: PMC1367164pubmed: 16439553
                    31. Halpin K, Hyatt AD, Fogarty R, Middleton D, Bingham J, Epstein JH, Rahman SA, Hughes T, Smith C, Field HE, Daszak P, The H. Pteropid Bats are Confirmed as the Reservoir Hosts of Henipaviruses: A Comprehensive Experimental Study of Virus Transmission.. Am J Trop Med Hyg 2011;85:946–951.
                      pmc: PMC3205647pubmed: 22049055
                    32. Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server.. Nat Protoc 2009;4:363–371.
                      pubmed: 19247286
                    33. Lee B, Ataman ZA. Modes of paramyxovirus fusion: a Henipavirus perspective.. Trends Microbiol 2011;19:389–399.
                      pmc: PMC3264399pubmed: 21511478
                    34. Luby SP, Gurley ES. Epidemiology of henipavirus disease in humans.. Curr Top Microbiol Immunol 2012;359:25–40.
                      pubmed: 22752412
                    35. Luby SP, Hossain MJ, Gurley ES, Ahmed BN, Banu S, Khan SU, Homaira N, Rota PA, Rollin PE, Comer JA, Kenah E, Ksiazek TG, Rahman M. Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001–2007.. Emerg Infect Dis 2009;15:1229–1235.
                      pmc: PMC2815955pubmed: 19751584
                    36. McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, Middleton D, Feng YR, Broder CC, Wang LF, Bossart KN. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats.. Vaccine 2008;26:3842–3852.
                      pmc: PMC6186147pubmed: 18556094
                    37. Miles J. The Courier-Mail.com.au. Queensland Newspapers Pty Ltd, Brisbane; Queensland 4001, Australia: 2010. Hendra therapy for mum, daughter.
                    38. Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, Russell G, Green D, McEachern J, Pritchard LI, Eaton BT, Wang LF, Bossart KN, Broder CC. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine.. J Virol 2006;80:12293–12302.
                      pmc: PMC1676295pubmed: 17005664
                    39. Murray K, Selleck P, Hooper P, Hyatt A, Gould A, Gleeson L, Westbury H, Hiley L, Selvey L, Rodwell B. A morbillivirus that caused fatal disease in horses and humans.. Science 1995;268:94–97.
                      pubmed: 7701348
                    40. O’Sullivan JD, Allworth AM, Paterson DL, Snow TM, Boots R, Gleeson LJ, Gould AR, Hyatt AD, Bradfield J. Fatal encephalitis due to novel paramyxovirus transmitted from horses.. Lancet 1997;349:93–95.
                      pubmed: 8996421
                    41. Pager CT, Wurth MA, Dutch RE. Subcellular localization and calcium and pH requirements for proteolytic processing of the Hendra virus fusion protein.. J Virol 2004;78:9154–9163.
                      pmc: PMC506929pubmed: 15308711
                    42. Pallister J, Middleton D, Broder CC, Wang LF. Henipavirus Vaccine Development.. J Bioterr Biodef 2011a:S1.
                    43. Pallister J, Middleton D, Crameri G, Yamada M, Klein R, Hancock TJ, Foord A, Shiell B, Michalski W, Broder CC, Wang LF. Chloroquine administration does not prevent Nipah virus infection and disease in ferrets.. J Virol 2009;83:11979–11982.
                      pmc: PMC2772715pubmed: 19759137
                    44. Pallister J, Middleton D, Wang LF, Klein R, Haining J, Robinson R, Yamada M, White J, Payne J, Feng YR, Chan YP, Broder CC. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge.. Vaccine 2011b;29:5623–5630.
                      pmc: PMC3153950pubmed: 21689706
                    45. Pernet O, Wang YE, Lee B. Henipavirus receptor usage and tropism.. Curr Top Microbiol Immunol 2012;359:59–78.
                      pmc: PMC3587688pubmed: 22695915
                    46. Playford EG, McCall B, Smith G, Slinko V, Allen G, Smith I, Moore F, Taylor C, Kung YH, Field H. Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008.. Emerg Infect Dis 2010;16:219–223.
                      pmc: PMC2957996pubmed: 20113550
                    47. Porotto M, Orefice G, Yokoyama CC, Mungall BA, Realubit R, Sganga ML, Aljofan M, Whitt M, Glickman F, Moscona A. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy.. J Virol 2009;83:5148–5155.
                      pmc: PMC2682105pubmed: 19264786
                    48. Rockx B, Bossart KN, Feldmann F, Geisbert JB, Hickey AC, Brining D, Callison J, Safronetz D, Marzi A, Kercher L, Long D, Broder CC, Feldmann H, Geisbert TW. A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment.. J Virol 2010;84:9831–9839.
                      pmc: PMC2937751pubmed: 20660198
                    49. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.. Science 1972;177:705–706.
                      pubmed: 4340949
                    50. Snell NJ. Ribavirin--current status of a broad spectrum antiviral agent.. Expert Opin Pharmacother 2001;2:1317–1324.
                      pubmed: 11585000
                    51. Wang L-F, Mackenzie JS, Broder CC. Henipaviruses.. In: Knipe DM, Howley PM, editors. Fields Virology. Lippincott Williams & Wilkins; Philadelphia: 2013. pp. 1070–1085.
                    52. Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, Czub M. Recombinant nipah virus vaccines protect pigs against challenge.. J Virol 2006;80:7929–7938.
                      pmc: PMC1563797pubmed: 16873250
                    53. Weingartl HM, Berhane Y, Czub M. Animal models of henipavirus infection: a review.. Vet J 2009;181:211–220.
                      pubmed: 19084436
                    54. Wong KT. Emerging epidemic viral encephalitides with a special focus on henipaviruses.. Acta Neuropathol 2010;120:317–325.
                      pmc: PMC7086526pubmed: 20652579
                    55. Wong KT, Ong KC. Pathology of acute henipavirus infection in humans and animals.. Patholog Res Int 2011;2011:567248.
                      pmc: PMC3180787pubmed: 21961078
                    56. Wong KT, Robertson T, Ong BB, Chong JW, Yaiw KC, Wang LF, Ansford AJ, Tannenberg A. Human Hendra virus infection causes acute and relapsing encephalitis.. Neuropathol Appl Neurobiol 2009;35:296–305.
                      pubmed: 19473296
                    57. Wright PJ, Crameri G, Eaton BT. RNA synthesis during infection by Hendra virus: an examination by quantitative real-time PCR of RNA accumulation, the effect of ribavirin and the attenuation of transcription.. Arch Virol 2005;150:521–532.
                      pubmed: 15526144
                    58. Xu K, Broder CC, Nikolov DB. Ephrin-B2 and ephrin-B3 as functional henipavirus receptors.. Semin Cell Dev Biol 2012a;23:116–123.
                      pmc: PMC3327611pubmed: 22227101
                    59. Xu K, Chan YP, Rajashankar KR, Khetawat D, Yan L, Kolev MV, Broder CC, Nikolov DB. New insights into the hendra virus attachment and entry process from structures of the virus g glycoprotein and its complex with ephrin-b2.. PLoS One 2012b;7:e48742.
                      pmc: PMC3489827pubmed: 23144952
                    60. Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, Feng Y, Middleton D, Wang LF, Broder CC, Dimitrov DS. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody.. J Infect Dis 2008;197:846–853.
                      pmc: PMC7199872pubmed: 18271743
                    61. Zhu Z, Prabakaran P, Chen W, Broder CC, Gong R, Dimitrov DS. Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.. Virologica Sinica 2013;28:71–80.
                      pmc: PMC7090799pubmed: 23575729

                    Citations

                    This article has been cited 70 times.
                    1. Lotfalizadeh N, Santucciu C, Chisu V, Sepahvand H, Rahdar A, Behzadmehr R, Franco OL, Moez G, Ferreira LFR. Advances in Microbial Diagnostics: Machine Learning and Nanotechnology for Zoonotic Disease Control. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2026 Jan-Feb;18(1):e70050.
                      doi: 10.1002/wnan.70050pubmed: 41572428google scholar: lookup
                    2. Zobayer A, Riyad MMH, Mia MJ, Ariful Kabir KM. Evaluating socioeconomic influences on Nipah virus vaccination decisions in Bangladesh through machine learning. J Health Popul Nutr 2025 Sep 29;44(1):328.
                      doi: 10.1186/s41043-025-01079-8pubmed: 41023771google scholar: lookup
                    3. Levine CB, Sauer LM, McLellan SLF, Evans JD. Nipah virus: a summary for clinicians. Int J Emerg Med 2025 Jul 9;18(1):126.
                      doi: 10.1186/s12245-025-00916-1pubmed: 40634915google scholar: lookup
                    4. Sharma S, Yadav PD, Cherian S. Comprehensive immunoinformatics and bioinformatics strategies for designing a multi-epitope based vaccine targeting structural proteins of Nipah virus. Front Immunol 2025;16:1535322.
                      doi: 10.3389/fimmu.2025.1535322pubmed: 40433372google scholar: lookup
                    5. Xie M, Younas Khan M, Ullah S, Farooq M, Riaz MB, Alwan BA. Optimal control analysis for the transmission of Nipah infection with imperfect vaccination. PLoS One 2025;20(4):e0317408.
                      doi: 10.1371/journal.pone.0317408pubmed: 40239175google scholar: lookup
                    6. Kane Y, Nalikka B, Tendu A, Omondi V, Bienes KM, Padane A, Duong V, Berthet N, Wong G. Genetic Diversity and Geographic Spread of Henipaviruses. Emerg Infect Dis 2025 Mar;31(3):427-437.
                      doi: 10.3201/eid3103.241134pubmed: 40023785google scholar: lookup
                    7. Branda F, Ceccarelli G, Giovanetti M, Albanese M, Binetti E, Ciccozzi M, Scarpa F. Nipah Virus: A Zoonotic Threat Re-Emerging in the Wake of Global Public Health Challenges. Microorganisms 2025 Jan 9;13(1).
                      doi: 10.3390/microorganisms13010124pubmed: 39858892google scholar: lookup
                    8. Spengler JR, Lo MK, Welch SR, Spiropoulou CF. Henipaviruses: epidemiology, ecology, disease, and the development of vaccines and therapeutics. Clin Microbiol Rev 2025 Mar 13;38(1):e0012823.
                      doi: 10.1128/cmr.00128-23pubmed: 39714175google scholar: lookup
                    9. Ma AZ, Yeo YY, Lee JF, Kim CM, Ezzatpour S, Menchaca C, Upadhye V, Annand EJ, Eden J-S, Plowright RK, Peel AJ, Buchholz DW, Aguilar HC. Functional assessment of the glycoproteins of a novel Hendra virus variant reveals contrasting fusogenic capacities of the receptor-binding and fusion glycoproteins. mBio 2025 Feb 5;16(2):e0348223.
                      doi: 10.1128/mbio.03482-23pubmed: 39704501google scholar: lookup
                    10. Rahman MA, Shanjana Y, Cronmiller S, Zong D, Davis R, Ernest J, Nguyen J, Rawa A, Thomas MR, Islam MR. Risk Evaluation and Mitigation Strategies for Potential Outbreaks of Nipah Virus Infection: Evidenced by the Recent Incidences in Southeast Asian Countries. Health Sci Rep 2024 Dec;7(12):e70239.
                      doi: 10.1002/hsr2.70239pubmed: 39633840google scholar: lookup
                    11. Wang S, Li W, Wang Z, Yang W, Li E, Xia X, Yan F, Chiu S. Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control. Signal Transduct Target Ther 2024 Sep 11;9(1):223.
                      doi: 10.1038/s41392-024-01917-xpubmed: 39256346google scholar: lookup
                    12. Kumar A, Misra G, Mohandas S, Yadav PD. Multi-epitope vaccine design using in silico analysis of glycoprotein and nucleocapsid of NIPAH virus. PLoS One 2024;19(5):e0300507.
                      doi: 10.1371/journal.pone.0300507pubmed: 38728300google scholar: lookup
                    13. Choudhary OP, Priyanka, Abu Salah MAH, Chopra H. One health and bat-borne henipaviruses. New Microbes New Infect 2024 Jan;56:101195.
                      doi: 10.1016/j.nmni.2023.101195pubmed: 38035121google scholar: lookup
                    14. Kaza B, Aguilar HC. Pathogenicity and virulence of henipaviruses. Virulence 2023 Dec;14(1):2273684.
                      doi: 10.1080/21505594.2023.2273684pubmed: 37948320google scholar: lookup
                    15. Lo MK. Utilizing Recombinant Reporter Henipaviruses to Conduct Antiviral Screening. Methods Mol Biol 2023;2682:87-92.
                      doi: 10.1007/978-1-0716-3283-3_6pubmed: 37610575google scholar: lookup
                    16. Amaya M, Broder CC, Laing ED. Recombinant Cedar Virus: A Henipavirus Reverse Genetics Platform. Methods Mol Biol 2023;2682:73-86.
                      doi: 10.1007/978-1-0716-3283-3_5pubmed: 37610574google scholar: lookup
                    17. Satterfield BA, Mire CE, Geisbert TW. Overview of Experimental Vaccines and Antiviral Therapeutics for Henipavirus Infection. Methods Mol Biol 2023;2682:1-22.
                      doi: 10.1007/978-1-0716-3283-3_1pubmed: 37610570google scholar: lookup
                    18. Li H, Kim JV, Pickering BS. Henipavirus zoonosis: outbreaks, animal hosts and potential new emergence. Front Microbiol 2023;14:1167085.
                      doi: 10.3389/fmicb.2023.1167085pubmed: 37529329google scholar: lookup
                    19. Cui Y, Li J, Guo J, Pan Y, Tong X, Liu C, Wang D, Xu W, Shi Y, Ji Y, Qiu Y, Yang X, Hou L, Zhou J, Feng X, Wang Y, Liu J. Evolutionary Origin, Genetic Recombination, and Phylogeography of Porcine Kobuvirus. Viruses 2023 Jan 14;15(1).
                      doi: 10.3390/v15010240pubmed: 36680281google scholar: lookup
                    20. Gazal S, Sharma N, Gazal S, Tikoo M, Shikha D, Badroo GA, Rashid M, Lee SJ. Nipah and Hendra Viruses: Deadly Zoonotic Paramyxoviruses with the Potential to Cause the Next Pandemic. Pathogens 2022 Nov 25;11(12).
                      doi: 10.3390/pathogens11121419pubmed: 36558753google scholar: lookup
                    21. Ithinji DG, Buchholz DW, Ezzatpour S, Monreal IA, Cong Y, Sahler J, Bangar AS, Imbiakha B, Upadhye V, Liang J, Ma A, Bradel-Tretheway B, Kaza B, Yeo YY, Choi EJ, Johnston GP, Huzella L, Kollins E, Dixit S, Yu S, Postnikova E, Ortega V, August A, Holbrook MR, Aguilar HC. Multivalent viral particles elicit safe and efficient immunoprotection against Nipah Hendra and Ebola viruses. NPJ Vaccines 2022 Dec 17;7(1):166.
                      doi: 10.1038/s41541-022-00588-5pubmed: 36528644google scholar: lookup
                    22. Pelegrin M, Marsile-Medun S, Abba-Moussa D, Souchard M, Naranjo-Gomez M. Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses. Antibodies (Basel) 2022 Jul 26;11(3).
                      doi: 10.3390/antib11030050pubmed: 35892710google scholar: lookup
                    23. Johnson K, Vu M, Freiberg AN. Recent advances in combating Nipah virus. Fac Rev 2021;10:74.
                      doi: 10.12703/r/10-74pubmed: 34632460google scholar: lookup
                    24. Frank I, Cigoli M, Arif MS, Fahlberg MD, Maldonado S, Calenda G, Pegu A, Yang ES, Rawi R, Chuang GY, Geng H, Liu C, Zhou T, Kwong PD, Arthos J, Cicala C, Grasperge BF, Blanchard JL, Gettie A, Fennessey CM, Keele BF, Vaccari M, Hope TJ, Fauci AS, Mascola JR, Martinelli E. Blocking α(4)β(7) integrin delays viral rebound in SHIV(SF162P3)-infected macaques treated with anti-HIV broadly neutralizing antibodies. Sci Transl Med 2021 Aug 18;13(607).
                      doi: 10.1126/scitranslmed.abf7201pubmed: 34408080google scholar: lookup
                    25. Halpin K, Graham K, Durr PA. Sero-Monitoring of Horses Demonstrates the Equivac(®) HeV Hendra Virus Vaccine to Be Highly Effective in Inducing Neutralising Antibody Titres. Vaccines (Basel) 2021 Jul 2;9(7).
                      doi: 10.3390/vaccines9070731pubmed: 34358146google scholar: lookup
                    26. Al-Halhouli A, Albagdady A, Alawadi J, Abeeleh MA. Monitoring Symptoms of Infectious Diseases: Perspectives for Printed Wearable Sensors. Micromachines (Basel) 2021 May 27;12(6).
                      doi: 10.3390/mi12060620pubmed: 34072174google scholar: lookup
                    27. Cheliout Da Silva S, Yan L, Dang HV, Xu K, Epstein JH, Veesler D, Broder CC. Functional Analysis of the Fusion and Attachment Glycoproteins of Mojiang Henipavirus. Viruses 2021 Mar 22;13(3).
                      doi: 10.3390/v13030517pubmed: 33809833google scholar: lookup
                    28. Dong J, Cross RW, Doyle MP, Kose N, Mousa JJ, Annand EJ, Borisevich V, Agans KN, Sutton R, Nargi R, Majedi M, Fenton KA, Reichard W, Bombardi RG, Geisbert TW, Crowe JE Jr. Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein. Cell 2020 Dec 10;183(6):1536-1550.e17.
                      doi: 10.1016/j.cell.2020.11.023pubmed: 33306954google scholar: lookup
                    29. Epstein JH, Anthony SJ, Islam A, Kilpatrick AM, Ali Khan S, Balkey MD, Ross N, Smith I, Zambrana-Torrelio C, Tao Y, Islam A, Quan PL, Olival KJ, Khan MSU, Gurley ES, Hossein MJ, Field HE, Fielder MD, Briese T, Rahman M, Broder CC, Crameri G, Wang LF, Luby SP, Lipkin WI, Daszak P. Nipah virus dynamics in bats and implications for spillover to humans. Proc Natl Acad Sci U S A 2020 Nov 17;117(46):29190-29201.
                      doi: 10.1073/pnas.2000429117pubmed: 33139552google scholar: lookup
                    30. Tit-Oon P, Tharakaraman K, Artpradit C, Godavarthi A, Sungkeeree P, Sasisekharan V, Kerdwong J, Miller NL, Mahajan B, Khongmanee A, Ruchirawat M, Sasisekharan R, Fuangthong M. Prediction of the binding interface between monoclonal antibody m102.4 and Nipah attachment glycoprotein using structure-guided alanine scanning and computational docking. Sci Rep 2020 Oct 26;10(1):18256.
                      doi: 10.1038/s41598-020-75056-ypubmed: 33106487google scholar: lookup
                    31. Liang B. Structures of the Mononegavirales Polymerases. J Virol 2020 Oct 27;94(22).
                      doi: 10.1128/JVI.00175-20pubmed: 32847861google scholar: lookup
                    32. Loomis RJ, Stewart-Jones GBE, Tsybovsky Y, Caringal RT, Morabito KM, McLellan JS, Chamberlain AL, Nugent ST, Hutchinson GB, Kueltzo LA, Mascola JR, Graham BS. Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. Front Immunol 2020;11:842.
                      doi: 10.3389/fimmu.2020.00842pubmed: 32595632google scholar: lookup
                    33. Mohammed AA, Shantier SW, Mustafa MI, Osman HK, Elmansi HE, Osman IA, Mohammed RA, Abdelrhman FA, Elnnewery ME, Yousif EM, Mustafa MM, Elfadol NM, Abdalla AI, Mahmoud E, Yagaub AA, Ahmed YA, Hassan MA. Epitope-Based Peptide Vaccine against Glycoprotein G of Nipah Henipavirus Using Immunoinformatics Approaches. J Immunol Res 2020;2020:2567957.
                      doi: 10.1155/2020/2567957pubmed: 32377531google scholar: lookup
                    34. Pedrera M, Macchi F, McLean RK, Franceschi V, Thakur N, Russo L, Medfai L, Todd S, Tchilian EZ, Audonnet JC, Chappell K, Isaacs A, Watterson D, Young PR, Marsh GA, Bailey D, Graham SP, Donofrio G. Bovine Herpesvirus-4-Vectored Delivery of Nipah Virus Glycoproteins Enhances T Cell Immunogenicity in Pigs. Vaccines (Basel) 2020 Mar 2;8(1).
                      doi: 10.3390/vaccines8010115pubmed: 32131403google scholar: lookup
                    35. Gupta AK, Kumar A, Rajput A, Kaur K, Dar SA, Thakur A, Megha K, Kumar M. NipahVR: a resource of multi-targeted putative therapeutics and epitopes for the Nipah virus. Database (Oxford) 2020 Jan 1;2020.
                      doi: 10.1093/database/baz159pubmed: 32090261google scholar: lookup
                    36. Lo MK, Amblard F, Flint M, Chatterjee P, Kasthuri M, Li C, Russell O, Verma K, Bassit L, Schinazi RF, Nichol ST, Spiropoulou CF. Potent in vitro activity of β-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus. Antiviral Res 2020 Mar;175:104712.
                      doi: 10.1016/j.antiviral.2020.104712pubmed: 31935422google scholar: lookup
                    37. Ojha R, Pareek A, Pandey RK, Prusty D, Prajapati VK. Strategic Development of a Next-Generation Multi-Epitope Vaccine To Prevent Nipah Virus Zoonotic Infection. ACS Omega 2019 Aug 20;4(8):13069-13079.
                      doi: 10.1021/acsomega.9b00944pubmed: 31460434google scholar: lookup
                    38. Mourya DT, Yadav PD, Ullas PT, Bhardwaj SD, Sahay RR, Chadha MS, Shete AM, Jadhav S, Gupta N, Gangakhedkar RR, Khasnobis P, Singh SK. Emerging/re-emerging viral diseases & new viruses on the Indian horizon. Indian J Med Res 2019 Apr;149(4):447-467.
                      doi: 10.4103/ijmr.IJMR_1239_18pubmed: 31411169google scholar: lookup
                    39. Dighe A, Jombart T, Van Kerkhove MD, Ferguson N. A systematic review of MERS-CoV seroprevalence and RNA prevalence in dromedary camels: Implications for animal vaccination. Epidemics 2019 Dec;29:100350.
                      doi: 10.1016/j.epidem.2019.100350pubmed: 31201040google scholar: lookup
                    40. Khandia R, Singhal S, Kumar U, Ansari A, Tiwari R, Dhama K, Das J, Munjal A, Singh RK. Analysis of Nipah Virus Codon Usage and Adaptation to Hosts. Front Microbiol 2019;10:886.
                      doi: 10.3389/fmicb.2019.00886pubmed: 31156564google scholar: lookup
                    41. Singh RK, Dhama K, Chakraborty S, Tiwari R, Natesan S, Khandia R, Munjal A, Vora KS, Latheef SK, Karthik K, Singh Malik Y, Singh R, Chaicumpa W, Mourya DT. Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review. Vet Q 2019 Dec;39(1):26-55.
                      doi: 10.1080/01652176.2019.1580827pubmed: 31006350google scholar: lookup
                    42. Bradel-Tretheway BG, Zamora JLR, Stone JA, Liu Q, Li J, Aguilar HC. Nipah and Hendra Virus Glycoproteins Induce Comparable Homologous but Distinct Heterologous Fusion Phenotypes. J Virol 2019 Jul 1;93(13).
                      doi: 10.1128/JVI.00577-19pubmed: 30971473google scholar: lookup
                    43. Kerry RG, Malik S, Redda YT, Sahoo S, Patra JK, Majhi S. Nano-based approach to combat emerging viral (NIPAH virus) infection. Nanomedicine 2019 Jun;18:196-220.
                      doi: 10.1016/j.nano.2019.03.004pubmed: 30904587google scholar: lookup
                    44. Mazzola LT, Kelly-Cirino C. Diagnostics for Nipah virus: a zoonotic pathogen endemic to Southeast Asia. BMJ Glob Health 2019;4(Suppl 2):e001118.
                      doi: 10.1136/bmjgh-2018-001118pubmed: 30815286google scholar: lookup
                    45. McLean RK, Graham SP. Vaccine Development for Nipah Virus Infection in Pigs. Front Vet Sci 2019;6:16.
                      doi: 10.3389/fvets.2019.00016pubmed: 30778392google scholar: lookup
                    46. Saha N, Robev D, Mason EO, Himanen JP, Nikolov DB. Therapeutic potential of targeting the Eph/ephrin signaling complex. Int J Biochem Cell Biol 2018 Dec;105:123-133.
                      doi: 10.1016/j.biocel.2018.10.006pubmed: 30343150google scholar: lookup
                    47. Michelotti JM, Yeh KB, Beckham TR, Colby MM, Dasgupta D, Zuelke KA, Olinger GG. The Convergence of High-Consequence Livestock and Human Pathogen Research and Development: A Paradox of Zoonotic Disease. Trop Med Infect Dis 2018 May 30;3(2).
                      doi: 10.3390/tropicalmed3020055pubmed: 30274451google scholar: lookup
                    48. Donaldson H, Lucey D. Enhancing preparation for large Nipah outbreaks beyond Bangladesh: Preventing a tragedy like Ebola in West Africa. Int J Infect Dis 2018 Jul;72:69-72.
                      doi: 10.1016/j.ijid.2018.05.015pubmed: 29879523google scholar: lookup
                    49. Laing ED, Amaya M, Navaratnarajah CK, Feng YR, Cattaneo R, Wang LF, Broder CC. Rescue and characterization of recombinant cedar virus, a non-pathogenic Henipavirus species. Virol J 2018 Mar 27;15(1):56.
                      doi: 10.1186/s12985-018-0964-0pubmed: 29587789google scholar: lookup
                    50. Thakkar VD, Cox RM, Sawatsky B, da Fontoura Budaszewski R, Sourimant J, Wabbel K, Makhsous N, Greninger AL, von Messling V, Plemper RK. The Unstructured Paramyxovirus Nucleocapsid Protein Tail Domain Modulates Viral Pathogenesis through Regulation of Transcriptase Activity. J Virol 2018 Apr 15;92(8).
                      doi: 10.1128/JVI.02064-17pubmed: 29437959google scholar: lookup
                    51. Frantz PN, Teeravechyan S, Tangy F. Measles-derived vaccines to prevent emerging viral diseases. Microbes Infect 2018 Oct-Nov;20(9-10):493-500.
                      doi: 10.1016/j.micinf.2018.01.005pubmed: 29410084google scholar: lookup
                    52. Walpita P, Cong Y, Jahrling PB, Rojas O, Postnikova E, Yu S, Johns L, Holbrook MR. A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model. NPJ Vaccines 2017;2:21.
                      doi: 10.1038/s41541-017-0023-7pubmed: 29263876google scholar: lookup
                    53. Guillaume-Vasselin V, Lemaitre L, Dhondt KP, Tedeschi L, Poulard A, Charreyre C, Horvat B. Protection from Hendra virus infection with Canarypox recombinant vaccine. NPJ Vaccines 2016;1:16003.
                      doi: 10.1038/npjvaccines.2016.3pubmed: 29263849google scholar: lookup
                    54. Ewer K, Sebastian S, Spencer AJ, Gilbert S, Hill AVS, Lambe T. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Hum Vaccin Immunother 2017 Dec 2;13(12):3020-3032.
                      doi: 10.1080/21645515.2017.1383575pubmed: 29083948google scholar: lookup
                    55. Goyen KA, Wright JD, Cunneen A, Henning J. Playing with fire - What is influencing horse owners' decisions to not vaccinate their horses against deadly Hendra virus infection?. PLoS One 2017;12(6):e0180062.
                      doi: 10.1371/journal.pone.0180062pubmed: 28636633google scholar: lookup
                    56. Thibault PA, Watkinson RE, Moreira-Soto A, Drexler JF, Lee B. Zoonotic Potential of Emerging Paramyxoviruses: Knowns and Unknowns. Adv Virus Res 2017;98:1-55.
                      doi: 10.1016/bs.aivir.2016.12.001pubmed: 28433050google scholar: lookup
                    57. De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev 2016 Jul;29(3):695-747.
                      doi: 10.1128/CMR.00102-15pubmed: 27281742google scholar: lookup
                    58. Broder CC, Weir DL, Reid PA. Hendra virus and Nipah virus animal vaccines. Vaccine 2016 Jun 24;34(30):3525-34.
                      doi: 10.1016/j.vaccine.2016.03.075pubmed: 27154393google scholar: lookup
                    59. Zahoor B. Rebuttal to Peel et al. Re: 'The imperative to develop a human vaccine for the Hendra virus in Australia'. Infect Ecol Epidemiol 2016;6:31659.
                      doi: 10.3402/iee.v6.31659pubmed: 27151274google scholar: lookup
                    60. Peel AJ, Field HE, Reid PA, Plowright RK, Broder CC, Skerratt LF, Hayman DT, Restif O, Taylor M, Martin G, Crameri G, Smith I, Baker M, Marsh GA, Barr J, Breed AC, Wood JL, Dhand N, Toribio JA, Cunningham AA, Fulton I, Bryden WL, Secombe C, Wang LF. The equine Hendra virus vaccine remains a highly effective preventative measure against infection in horses and humans: 'The imperative to develop a human vaccine for the Hendra virus in Australia'. Infect Ecol Epidemiol 2016;6:31658.
                      doi: 10.3402/iee.v6.31658pubmed: 27151273google scholar: lookup
                    61. Zahoor BA, Mudie LI. The imperative to develop a human vaccine for the Hendra virus in Australia. Infect Ecol Epidemiol 2015;5:29619.
                      doi: 10.3402/iee.v5.29619pubmed: 26519254google scholar: lookup
                    62. Pelegrin M, Naranjo-Gomez M, Piechaczyk M. Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?. Trends Microbiol 2015 Oct;23(10):653-665.
                      doi: 10.1016/j.tim.2015.07.005pubmed: 26433697google scholar: lookup
                    63. Ong KC, Wong KT. Henipavirus Encephalitis: Recent Developments and Advances. Brain Pathol 2015 Sep;25(5):605-13.
                      doi: 10.1111/bpa.12278pubmed: 26276024google scholar: lookup
                    64. Pearce LA, Yu M, Waddington LJ, Barr JA, Scoble JA, Crameri GS, McKinstry WJ. Structural characterization by transmission electron microscopy and immunoreactivity of recombinant Hendra virus nucleocapsid protein expressed and purified from Escherichia coli. Protein Expr Purif 2015 Dec;116:19-29.
                      doi: 10.1016/j.pep.2015.07.008pubmed: 26196500google scholar: lookup
                    65. Bradel-Tretheway BG, Liu Q, Stone JA, McInally S, Aguilar HC. Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus. J Virol 2015 Jul;89(14):7235-47.
                      doi: 10.1128/JVI.00773-15pubmed: 25948743google scholar: lookup
                    66. Dhillon J, Banerjee A. Controlling Nipah virus encephalitis in Bangladesh: Policy options. J Public Health Policy 2015 Aug;36(3):270-82.
                      doi: 10.1057/jphp.2015.13pubmed: 25925087google scholar: lookup
                    67. Enkirch T, von Messling V. Ferret models of viral pathogenesis. Virology 2015 May;479-480:259-70.
                      doi: 10.1016/j.virol.2015.03.017pubmed: 25816764google scholar: lookup
                    68. Lo MK, Nichol ST, Spiropoulou CF. Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening. Antiviral Res 2014 Jun;106:53-60.
                      doi: 10.1016/j.antiviral.2014.03.011pubmed: 24680955google scholar: lookup
                    69. McNabb L, Barr J, Crameri G, Juzva S, Riddell S, Colling A, Boyd V, Broder C, Wang LF, Lunt R. Henipavirus microsphere immuno-assays for detection of antibodies against Hendra virus. J Virol Methods 2014 May;200:22-8.
                      doi: 10.1016/j.jviromet.2014.01.010pubmed: 24508193google scholar: lookup
                    70. Lo MK, Bird BH, Chattopadhyay A, Drew CP, Martin BE, Coleman JD, Rose JK, Nichol ST, Spiropoulou CF. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Res 2014 Jan;101:26-9.
                      doi: 10.1016/j.antiviral.2013.10.012pubmed: 24184127google scholar: lookup
                    Subscribe to our newsletter
                    Join 99,001 horse owners like you who receive our email updates on horse health and nutrition.